We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+54.07%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$110M
Cap. Flow
+$63.1M
Cap. Flow %
28.27%
Top 10 Hldgs %
78.3%
Holding
30
New
7
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$26.4M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$11.8M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$5.97M
4
HRTX icon
Heron Therapeutics
HRTX
+$3.71M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.82M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.99M
2
ACHC icon
Acadia Healthcare
ACHC
+$6.52M
3
TSRO
TESARO, Inc.
TSRO
+$3.74M
4
CARM
Carisma Therapeutics
CARM
+$931K
5
ARDM
Aradigm Corp Common Stock
ARDM
+$832K

Sector Composition

Rank Sector Weight
1 Healthcare 75.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONTXW
26
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$242K 0.11%
+241,644
New +$256K
EPIX
27
DELISTED
ESSA Pharma
EPIX
$74K 0.03%
1,405
– –
ACHC icon
28
Acadia Healthcare
ACHC
$2.76B
– –
-200,938
Closed -$6.52M
REGN icon
29
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-20,000
Closed -$6.99M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Boxer Capital held 30 positions worth $223M, up 98% from $113M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Boxer Capital deployed $63.1M of net new capital in Q3 2016, opening 7 new positions and adding to 5 existing holdings. Its largest new stake was Medicines Co: 700,000 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was TESARO, Inc., an estimated $3.74M trimmed.

  • Boxer Capital's largest Q3 2016 buy was Medicines Co: 700,000 shares worth $26.4M.
  • Boxer Capital added most to Clovis Oncology, Inc. in Q3 2016, an estimated $11.8M increase.
  • Boxer Capital's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $3.74M.
  • Boxer Capital fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $6.99M.
  • Boxer Capital's ten largest holdings make up 78% of its $223M portfolio in Q3 2016.
  • Boxer Capital opened 7 new positions and closed 2 in Q3 2016.
  • Boxer Capital's portfolio value rose 98% quarter-over-quarter to $223M.

Based on Boxer Capital's 13F filing for Q3 2016, filed 14 Nov 2016.